Best performers of the SBF 120: Genfit stock advances by nearly 4%
The Lille-based biotech company specializing in hepatic and metabolic diseases is recovering in early afternoon trading, in a rising Paris market. This rebound comes after a month of severe correction, which has left the stock far from its moving averages.
A rebound of 3.93% that erases only a small portion of the monthly decline
The Genfit stock gains 3.93% to €8.46, against €8.14 the previous day. It thus ranks among the strongest gainers of the SBF 120, which advances by 0.38% at the same time. The surge remains modest compared to the 28.06% drop over one month and 37.79% over three months: it mitigates the decline without offsetting it. Over the week, performance stands at 1.56%.
The stock is trading 8.74% below its 20-day moving average at €9.27, and 12.69% below its 200-day moving average at €9.69. The RSI at 30.70 reflects the scale of the recent decline, and the support level at €7.83 sits approximately 7.4% below the current price. Among recent sessions, the 4% rebound on October 12 had also been followed by a new decline.
Short positions increase by 1.80 percentage points in one month, to 2.30% of capital
Three funds collectively hold 2.30% of capital sold short, according to declarations consulted, with the most recent dating from October 12. This total was 0.50% thirty days ago, representing an increase of 1.80 percentage points in one month, faster than the absolute level would suggest. This figure indicates that institutional investors are positioning themselves bearishly on the value, or seeking to hedge an exposure, but it says nothing of their motivations.
The recent decline also reflects a French market where the 10-year OAT reaches 4.74% at the close on October 15, or 1.35 percentage points above the Bund. Budget debates continue at the National Assembly. No financial milestone is mentioned in the data provided for the company: the level of €7.83 remains the nearest technical threshold in case of a further decline.
